Tempus AI, Inc. (TEM)
TEM Stock Gains 17.9% in a Year: Time to Buy, Hold or Sell?
Tempus AI rides on diagnostics growth, AI-driven data demand, and pricing gains - but persistent losses and valuation questions complicate the buy-or-sell call.
What's Driving TEM Data and Applications Arm's Robust Growth?
Tempus AI's data arm surges with 69.5% Insights growth, $1.1B+ contracts, and AI-driven expansion fueling strong revenue outlook and customer retention gains.
Tempus AI: A Dual-Engine AI Model
Tempus AI is a diagnostics and data platform leveraging a large healthcare dataset to inform clinical decision-making. Strong 2025 performance driven by diagnostics growth, oncology re-acceleration, and Ambry Genetics acquisition. AI model reaching “critical mass” with 450+ petabytes of data, enabling new product expansion.
Tempus AI Stock Gains Following the ALERT Trial Result Announcement
TEM jumps after ALERT trial shows EHR alerts boost timely valve care, improving evaluations and interventions for aortic stenosis and MR patients.
What's Fueling TEM Diagnostics Segment's Strong 2026 Outlook?
TEM's diagnostics arm surges on oncology demand, MRD adoption and rising pricing, with 2026 growth set to stay strong as sequencing and reimbursement expand.
TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now?
Tempus AI TEM and Doximity DOCS are two well-established players in the Medical Information Systems industry, each with distinct niche. Tempus is focused on advancing precision medicine through artificial intelligence.
Tempus AI: An Attractive Entry Point At Current Prices
Tempus AI is rated Strong Buy with a $71 12-month price target, reflecting 67% upside after a 60% share price decline. TEM's integrated genomic and clinical data flywheel creates a defensible moat, reinforced by the Ambry Genetics acquisition and expanding pharma partnerships. Diagnostics revenue more than doubled YoY, while high-margin data and applications segments drive improving blended margins and record $1.1B TCV.
Tempus AI Reinforces Market Position With Collaborations in 2026
TEM expands 2026 reach via strategic collaborations, boosting oncology, diagnostics and AI-driven insights to enhance care and drug development.
Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?
Tempus (TEM) reported earnings 30 days ago. What's next for the stock?
Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story
Tempus AI's dual-engine model drives $1.27B revenues, with Diagnostics dominating and Data monetization accelerating growth and pricing leverage.
Tempus AI, Inc. $TEM Shares Bought by Bamco Inc. NY
Bamco Inc. NY raised its holdings in shares of Tempus AI, Inc. (NASDAQ: TEM) by 53.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 263,250 shares of the company's stock after buying an additional 92,007 shares during the quarter.
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.
